Loeb Partners Corp’s Nektar Therapeutics NKTR Stock Holding History

Loeb Partners Corp’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13	Closed	-$6K	–	90
2019 Q1	$6K	Buy	13 +10	+333%	+$5.93K	0.12%	94
2018 Q4	$2K	Buy	+3	New	+$1.81K	﹤0.01%	282

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Loeb Partners Corp's NKTR Position: Q2 2019 in Review

Loeb Partners Corp sold out of Nektar Therapeutics (NKTR) in Q2 2019, closing a stake of 13 shares — an estimated $6K sold.

Loeb Partners Corp first reported a position in NKTR in Q4 2018 and held it in 2 quarters. The position peaked at $6K in Q1 2019. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

Loeb Partners Corp reported no remaining Nektar Therapeutics position as of Q2 2019 after selling out during the quarter.
Loeb Partners Corp sold 13 Nektar Therapeutics shares in Q2 2019, an estimated $6K.
Loeb Partners Corp first reported a position in Nektar Therapeutics in Q4 2018 and held it in 2 quarters.
Loeb Partners Corp's Nektar Therapeutics position peaked at $6K in Q1 2019.
336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on Loeb Partners Corp's 13F filing for Q2 2019.